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THE TERM "cell" was coined in 1665 by Hooke' who described "fittl~ ?oxes ~r cells distinc.t from. one 
another" while examtnmg a pIece of cork wIth a mIcro-
SCOpe. The first ceU transplant in humans may have been a 
blood transfusion ~rformed in 1492. A story of ambiguous 
authenticity descnbes Pope Innocent VIII as the first 
recipient of a cell transplant. the blood transfusion donors 
being three youths. The donors and recipient passed on 
shortly thereafter, and the prescribing transplant physician 
disappeared in an unkno\\-o direction.2 
The world of cellular transplantation was pioneered by 
the early work in tissue culture and transplantation by 
Zahn (1878), Arnold EfUUTFK~ Williams (1893),4 Born (1896), 
Harrison (1905),3 and Carrel (1910).5 A milestone in cell 
transplant history was the introduction of proteolytic en-
zymes to dissociate tissues into single cells by Rous and 
Jones in 1916 who used trypsin to separate growing cells 
from tissue included in a plasma clot.6 Tissue had been 
arown by the technique of Carrel and Burrow as modified 
from Harrison's method.5 The liberation of the new cells 
by trypsin digestion was not widely accepted because of 
the fear of damaging the cells by the enzymatic treatment. 7 
Thirty years later, trypisinization and the isolation of 
collagenase from Clostridium welchii in 19468 opened the 
way to modem technology of cell separation and trans-
plantation (Table I). 
Several cellular-transplant models have been described 
(Table 2), and many of them share problems and advan-
tages, as can be exemplified with work on pancreatic islets. 
Separation and/or purification of an adequate number of 
intact islets is the first requirement.9 The second main 
problem has been the lack of effective procedures for early 
detection and treatment of rejection episodes. Because of 
I.he small cell mass, it is too late to treat a rejection episode 
When it becomes manifest by functional failure of the graft. 
This problem is particularly difficult when immature or 
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Table 1. Early Development In enzymatic Cell 
Sepa,.uon Methods 
Rous and Jones 
Oakley 
Rappaport 
Rinaldini 
Cell separation from 
plasma clot by proteo-
lytic digestion (IIypsin) 
Isolation of coIagenase 
from C. welchii 
Automatic meIhod fOl' the 
preparation 01 eeR sus-
pension (trypsinization of 
monkey kidney tissue) 
Purified collagenase; isola-
tion of living eens from 
animal tissues 
fetal cells are transplanted. Here. a significant gap exists 
beween the time of transplantation and the beginning of 
functional activity of the grafted cells. The fact that the 
transplant has been destroyed during this silent period is 
realized only when it does not function later. 
Despite these challenges. cellular transplantation offers 
several advantages compared with organ transplantation, 
of which the first is the ease of the surgical procedure 
which, in many cases, is a simple injection. In addition, it 
is possible to manipulate tissue in vitro before transplan-
tation to inactivate and'or destroy class II positive antigen-
presenting cells9• 13 (Table 3). 
Also, it may be feasible with encapsulation techiques to 
erect a physical barrier between the transplanted cells and 
the recipient's immune systems. 14-16 The application of the 
microencapsulation technology is currently limited by the 
need for materials that do not stimulate fibroblastic re-
sponse in the recipient. Macroencapsulation intravascular 
devices require nontrombogenic surfaces that are resistant 
to fibrin deposition while they maintain an effective inter-
face with blood and/or tissue ftuids. 
Another potential advantage of cellular transplant is the 
possibility of cryopreserving the cells. 17· 18 This would 
allow the creation of banks of tissue for use at a later time. 
This will be crucial where multiple donors are needed for 
an adequate number of cells. Besides answering quantita-
tive needs. transplantation from multiple donors has re-
sulted in induction of tolerance in experimental mod-
els. '9-20 
Appropriate sites for cellular transplantation are neces-
sary to ensure the adequate vascular support that is 
essential for integration and reconstitution of any biologic 
function. The site choice also may be immunologically 
relevant. and may inftuence the intensity of allograft and 
xenograft rejection and survival.2'-2s 
Recently, Thompson et al reported the formation of 
neovascular structures after implantation of fibers coated 
with collagen. and growth factors in the peritoneal cavity 
of rats. 26 These organoids have been capable of sustaining 
the biologic function of implanted hepatOCy1es. Besides 
providing a favorable environment for engraftment and 
function. organoids could be an alternative to diffuse 
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Table 2. Types of Cellular Transplants 
Adrenal 
Bone marrow 
Epidermal 
Endothelial 
Fibroblasts 
Hepatocytes 
Islets 
Lymphocytes 
Myoblasts 
Neural 
Parathyroid 
Stem cells 
intraperitoneal implantation of cells. making it possible to 
confine the cellular implant to a well-defined. vascularized 
space that could be easily removed in case of adverse 
reaction. This approach26 could be applied for the implan-
tation of autologous cells after restoration of a deficient 
function by gene transfer. 
Gene therapy is. in fact, a powerful first cousin of 
cellular transplantation that greatly amplified its potential 
applications. With gene therapy. viruses or other transfec-
ting agents. stripped of their deleterious functions. can be 
used as vehicles to introduce normal. functional genes into 
cultural human cells with deficient genomes and. thus. to 
cure genetic diseases. Recent reviews on the subject are 
available. 27-30 
Apart from gene therapy. the feasibility of somatic 
correction of inborn errors with cells has been demon-
strated beyond question by bone marrow transplantation 
of consanquineous and closely-matched allografts.29 Con-
sequently, bone marrow technology has been a magnet for 
studies of gene therapy. The more widely-studied possibil-
ities have been the immunodeficiency diseases caused by 
defects of adenosine deaminase and purine-nucleoside 
phosphorylase, chronic granulomatous diseases. and Gau-
cher's disease. Other diseases. such as en'throid cell 
disorders of hemoglobin expression, including sickle cell 
anemia and the thalassemias, could become also theoreti-
cal targets for gene therapy if appropriate regulation and 
efficient expression of globin genes can be introduced into 
the deficient, isologous bone marrow of the patients. This 
would provide the benefits of bone marrow allografts 
without the penalties of rejection and/or graft-versus-host 
disease. 
Because of its determinant role in the expression of 
Table 3. Immunoalteratlon Techniques 
Culture (95% O2, 24'C. hyperbaric. hyperthemWc) 
Cryopreservation 
Antibodies (anti-class II Ag. -dendritic cells. -1lJ 
Ultraviolet light. donor or tissue. irradiation 
Single cell dispersion and reaggregation 
Donor fatty acid deficiency 
Anti-oxygen-tree rad"1C8l reagents 
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many genetic and metabolic diseases.31 the liver is another 
target for gene therapyY Several genes have been ex-
pressed in primary hepatocyte cultures in vitro, including 
the disease-related genes for the human receptor for low-
density Iiproteins. phenylalanine hydroxylase, and alpha-
I-antitrypsin. Research efforts are now concentrated to 
develop efficient methods for the implantation of geneti-
cally-modified hepatOC)les. and/or to develop vectors that 
can be introduced directly into hepatocytes in vivo. Cor-
rection might then become possible without in vitro ge-
netic manipulation and cell reimplantation. 
Several models of gene therapy have been proposed for 
central nervous system genetic and nongenetic diseases. 27 
The genetic approaches to therapy of central nervous 
system disorders are of difficult application because most 
target cells are postmitotic (neurons) and, therefore. re-
fractory to infection with retroviral vectors. In addition. 
most disorders affecting the central nervous system func-
tion are probably multigenic and multifactorial. and the 
target cells are located in sites that are not easily accessi-
ble. Neurotrophic DNA viruses. such as herpes simplex 
virus. however. have exciting new potential for gene 
delivery to the central nervous system. In this case. 
apathogenic strains that establish life-long latent infections 
of brain cells while expressing only nonviral therapeutic 
genes from the latent "iral genomes are under develop-
ment (J .C. Glorioso. personal communication, August 
1990). Large DNA viruses have the advantage that multi-
ple minigene cassettes can be introduced in a site-specific 
manner and wiU be stably expressed without direct inte-
gration into neural cell chromosomes. 
Studies are now underway in many centers to examine 
the potential role of retrovirally transduced mouse nerve 
growth factor cDNA for the treatment of Alzheimer's 
disease. Similar approaches have been studied for the 
delivery of useful agents in models of Parkinson's disease. 
Gene therapy also has been proposed for cancer 
treatment. 27 Deficiencies of cancer-suppressor genes. such 
as those apparently associated v.;th retinoblastoma and 
Wilms' tumor. could be treated by restoration of the 
suppressor-gene expression. Other approaches involve 
inactivation of dominantly-acting oncogenes. 
Gene transfer could be used to endow cell transplants 
with new functions that they do not normally possess. For 
example. cultured fibroblast isografts could be reintro-
duced after the introduction of genes to replace defective 
hormones such as insulin.33 serum proteins. and other 
metabolic products. 
Another potential ad"antage of cellular transplantation 
is the possibility to use combined cellular transplants. In 
this case. a cell popUlation is transplanted to allow or 
improve the survival ofa second-cell type, as in the case of 
pancreatic islets that promote the survival of hepatocytes 
transplanted in ectopic sites.34 Moreover, adrenal cortical 
cells may provide local steroid secretionP~ to protect other 
cell types from rejection (unpublished observations). 
Time constraints make it impossible to review all cell-
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transplant applications. Pancreatic islet transplantation 
can be chosen to show that significant clinical progress is 
being made in the field. The procedures for isolation of the 
islet cells from exocrine tissue were pioneered by 
Moskalewskj36 and Lacy.3? In 1967. Lacy introduced the 
concept of pancreatic distension and collagenase digestion 
for islet preparation37 which remains the basis of isolation 
technology today.9.J8-4.C The most recent data of the islet 
allograft registry by Hering et al indicate that. before 1984. 
no islet transplant demonstrated significant islet function 
(basal C-peptide > I nglmL> I month after transplan-
tation.44 Twenty-six adult islet allografts were performed 
between 1985 and 1989. and. in over 30% of these cases. 
basal C-peptide production was observed in the first week 
posttransplant. However. less than 20% had documented 
C-peptide production I month after transplantation. 1990 
has been a critical year for islet transplantation. It was 
recently reported by the Washington University group that 
allogenic purified human islets transplanted intraportally 
had resulted in exogenous insulin independence for 2 
weeks in a patient with type I diabetes.4s At the University 
of Pittsburgh. (starting January 10. 1990) we performed a 
series of human islet allografts in nine patients who were 
diabetic as a result of an upper abdominal exenteration 
which included radical pancreatectomy that was per-
formed for extensive malignancies.46 These patients re-
ceived islet-cell allografts at the time of or just after the 
liver replacement. 47 They had monotherapy with FK 506 
for immunosuppression. As of August 15. 1990. six of the 
nine patients are alive, 132 to 217 days postoperatively. 
Five are insulin-free or are on insulin only during periodic 
parenteral alimentation. The first islet transplant of this 
series was performed in a IS-year-old girl who requires 
neither parenteral alimentation nor insulin. She received 
islets from a single donor (same as the liver) and. to our 
knowledge. is the first unequivocal example ofa successful 
islet-cell transplant in humans. It is noteworthy that both 
the donor and recipient were children. and also. that only 
a single islet donor was used. 
Significant C-peptide production was documented in all 
nine of the transplanted patients. Subsequently. three 
other centers (St Louis, Milan. Edmonton) have achieved 
prolonged insulin independence after islet allotransplanta-
tion in type I diabetic patients (P.E. Lacy. C. Socci, R. Y. 
Rajotte, personal communication, August 1990). This 
burst of results from four geographically-separated institu-
tions will be a stimulus for further clinical applications. 
The size and quality of the yield of islet cell mass has been 
improved, but other factors remain to be clarified. such as 
the adequacy of various implantation sites for islet engraft-
ment and revascularization; the diagnosis and treatment of 
rejection; and the diabetogenic affect of the immunosup-
pressive agents. including FK 506. cyclosporine. and. 
above all. steroids. 
Islet transplantation is an example of a cell transplant 
procedure that finally has reached the prospect of success 
in clinical trials this year after several decades of intensive 
75 
research. The unselfish exchange of information between 
centers and scientists have been fundamental to progress. 
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